{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:54:59Z","timestamp":1787586899223,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":353,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jlr.org"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1194\/jlr.m092486","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T21:45:11Z","timestamp":1562795111000},"page":"1610-1621","update-policy":"https:\/\/doi.org\/10.1194\/jlr.f110.005975","source":"Crossref","is-referenced-by-count":23,"title":["Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia"],"prefix":"10.1016","volume":"60","author":[{"given":"Victor","family":"Sokolov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Helmlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Zhudenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanko","family":"Skrtic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Hamr\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Peskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hurt-Camejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Jansson-L\u00f6fmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1194\/jlr.M092486_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4330\/wjc.v1.i1.3","article-title":"Cardiovascular disease: a global problem extending into the developing world","volume":"1","author":"Aje","year":"2009","journal-title":"World J. Cardiol."},{"key":"10.1194\/jlr.M092486_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0021-9150(98)00107-5","article-title":"Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis","volume":"139","author":"Camejo","year":"1998","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.M092486_bib3","doi-asserted-by":"crossref","first-page":"I7","DOI":"10.1002\/clc.4960261304","article-title":"New dimension of statin action on ApoB atherogenicity","volume":"26","author":"Chapman","year":"2003","journal-title":"Clin. Cardiol."},{"key":"10.1194\/jlr.M092486_bib4","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40265-016-0613-0","article-title":"Unmet needs in LDL-C lowering: when statins won't do!","volume":"76","author":"Kr\u00e4henb\u00fchl","year":"2016","journal-title":"Drugs."},{"key":"10.1194\/jlr.M092486_bib5","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1194\/jlr.M092486_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/14712598.2012.748743","article-title":"Anti-PCSK9 therapies for the treatment of hypercholesterolemia","volume":"13","author":"Hooper","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1194\/jlr.M092486_bib7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrd.2017.83","article-title":"Nine paths to PCSK9 inhibition","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1194\/jlr.M092486_bib8","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1038\/psp.2014.47","article-title":"A mechanistic systems pharmacology model for prediction of LDL cholesterol lowering by PCSK9 antagonism in human dyslipidemic populations","volume":"3","author":"Gadkar","year":"2014","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1194\/jlr.M092486_bib9","first-page":"1177","article-title":"A quantitative systems pharmacology platform to investigate the impact of alirocumab and cholesterol-lowering therapies on lipid profiles and plaque characteristics","volume":"11","author":"Ming","year":"2017","journal-title":"Gene Regul. Syst. Bio."},{"key":"10.1194\/jlr.M092486_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1752-0509-6-130","article-title":"A whole-body mathematical model of cholesterol metabolism and its age-associated dysregulation","volume":"6","author":"Mc Auley","year":"2012","journal-title":"BMC Syst. Biol."},{"key":"10.1194\/jlr.M092486_bib11","doi-asserted-by":"crossref","first-page":"e1003509","DOI":"10.1371\/journal.pcbi.1003509","article-title":"An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway","volume":"10","author":"Lu","year":"2014","journal-title":"PLOS Comput. Biol."},{"key":"10.1194\/jlr.M092486_bib12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1755-5922.12093","article-title":"A Randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects","volume":"32","author":"Lunven","year":"2014","journal-title":"Cardiovasc. Ther."},{"key":"10.1194\/jlr.M092486_bib13","doi-asserted-by":"crossref","first-page":"e003323","DOI":"10.1161\/JAHA.116.003323","article-title":"Relationship between low-density lipoprotein cholesterol, free proprotein convertase subtilisin\/kexin type 9, and alirocumab levels after different lipid-lowering strategies","volume":"5","author":"Rey","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1194\/jlr.M092486_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2217\/fca.13.107","article-title":"Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody","volume":"10","author":"Roth","year":"2014","journal-title":"Future Cardiol."},{"key":"10.1194\/jlr.M092486_bib15","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.M092486_bib16","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.M092486_bib17","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.M092486_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet."},{"key":"10.1194\/jlr.M092486_bib19","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1194\/jlr.M092486_bib20","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1194\/jlr.M092486_bib21","doi-asserted-by":"crossref","first-page":"e003421","DOI":"10.1161\/JAHA.116.003421","article-title":"Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study","volume":"5","author":"Stroes","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1194\/jlr.M092486_bib22","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","article-title":"Effects of AMG 145 on low-density lipoprotein cholesterol levels","volume":"60","author":"Dias","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.M092486_bib23","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet."},{"key":"10.1194\/jlr.M092486_bib24","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia","volume":"63","author":"Koren","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.M092486_bib25","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation."},{"key":"10.1194\/jlr.M092486_bib26","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA."},{"key":"10.1194\/jlr.M092486_bib27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.M092486_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet."},{"key":"10.1194\/jlr.M092486_bib29","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.M092486_bib30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/clc.22687","article-title":"A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin\/kexin type 9: RG7652, an anti-PCSK9 antibody, reduces LDL-C","volume":"40","author":"Baruch","year":"2017","journal-title":"Clin. Cardiol."},{"key":"10.1194\/jlr.M092486_bib31","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"Romagnuolo","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M092486_bib32","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1194\/jlr.M200055-JLR200","article-title":"Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects","volume":"43","author":"Cohn","year":"2002","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M092486_bib33","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1210\/jc.2003-032056","article-title":"Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity","volume":"89","author":"Cohn","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1194\/jlr.M092486_bib34","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1194\/jlr.R024075","article-title":"Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk","volume":"53","author":"Barter","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M092486_bib35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrendo.2010.50","article-title":"Diagnosis and treatment of apolipoprotein B dyslipoproteinemias","volume":"6","author":"Sniderman","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1194\/jlr.M092486_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1194\/jlr.M011445","article-title":"A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo","volume":"52","author":"Ni","year":"2011","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M092486_bib37","doi-asserted-by":"crossref","unstructured":"Kaschek, D., W. Mader, M. Fehling-Kaschek, M. Rosenblatt, and J. Timmer, . 2019. Dynamic modeling, parameter estimation and uncertainty analysis in R. bioRxiv 10.1101\/085001.","DOI":"10.18637\/jss.v088.i10"},{"key":"10.1194\/jlr.M092486_bib38","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1194\/jlr.M008144","article-title":"High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol","volume":"51","author":"Welder","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M092486_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem. Sci."},{"key":"10.1194\/jlr.M092486_bib40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1475-2840-10-20","article-title":"Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: discriminant ratio and unbiased equivalence","volume":"10","author":"Hermans","year":"2011","journal-title":"Cardiovasc. Diabetol."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520323221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520323221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1194\/jlr.M092486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T16:33:37Z","timestamp":1637426017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227520323221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0022227520323221"],"URL":"https:\/\/doi.org\/10.1194\/jlr.m092486","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}